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Factors responsible for initial success or failure of coro-
nary thrombolysis and persistent recanalization or early 
reocclusion have not been thoroughly elucidated. Both 
adequate initial clot lysis and preclusion of rethrombosis 
are required. Failure may reflect clot lysis followed im-
mediately or somewhat later by rethrombosis. To de-
termine whether differences in the intensity and persis-
tence of the activation of thrombin are determinants of 
success or failure of recanalization, plasma fibrinopep-
tide A, a fibrinogen product liberated by thrombin, was 
serially assayed in 19 patients treated with intravenous 
streptokinase. In patients exhibiting recanalization (n = 
9), plasma fibrinopeptide A decreased after administra-
tion of streptokinase but before administration of hep-
Factors responsible for the initial success or failure of throm-
bolysis and for early reocclusion have not been elucidated 
fully. Activation of plasminogen by itself may be sufficient 
for persistent recanalization without anticoagulation in some 
patients. In others, apparent failure of initial lysis or lack 
of persistence of recanalization may occur despite adequate 
activation of plasminogen (1) and may reflect intense or 
persistent activation of thrombin. 
Fibrinopeptide A is a small polypeptide liberated from 
fibrinogen by the action of thrombin (2). Elevation of plasma 
fibrinopeptide A is a marker of ongoing thrombosis (2-5). 
Early after the onset of acute transmural infarction, fibri-
nopeptide A is frequently elevated. Values then decrease 
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arin. In patients without initially apparent recanaliza-
tion, fibrinopeptide A increased, suggesting ongoing 
thrombosis, and subsequently decreased promptly after 
heparin. In patients with initial recanalization followed 
by overt reocclusion the pattern was different. Despite 
recanalization, fibrinopeptide A continued to rise mark-
edly. Elevations persisted despite administration of hep-
arin. Thus, inhibition of activation of thrombin is as-
sociated with successful recanalization. Conversely, per-
sistent activation of thrombin may be a predisposing 
factor to both apparent initial failure of recanalization 
and overt early reocclusion. 
(J Am Coli CardioI1986;7:1255-62) 
over 24 hours (6). Elevations of fibrinopeptide A indicative 
of ongoing intravascular coagulation decrease promptly in 
response to administration of heparin because of inhibition 
of thrombin coupled with the short half-life (3 to 5 minutes) 
of circulating fibrinopeptide A (6,7). Patients with angio-
graphically documented coronary thrombosis consistently 
manifest marked elevations of plasma fibrinopeptide A. Thus, 
in the setting of acute transmural infarction, fibrinopeptide 
A appears to be a marker of coronary thrombosis (6). 
To identify relations among ongoing thrombosis, initial 
success or failure of coronary thrombolysis and early reoc-
clusion after initial recanalization, we assayed plasma fi-
brinopeptide A serially in 19 patients treated with intrave-
nous streptokinase. We hypothesized that initial failure of 
thrombolysis and early reocclusion might reflect intense or 
persistent activation of thrombin in vivo. Cross-reactivity 
of fibrinogen degradation products in the fibrinopeptide A 
immunoassay was excluded. Results indicated that suc-
cessful recanalization is associated with a prompt diminution 
of activation of thrombin. In contrast, persistent activation 
of thrombin is associated with and is a potential determinant 
of initial failure of coronary thrombolysis and of early reoc-
clusion. 
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Methods 
Study patients. The clinical protocol employed in this 
study was approved by the Washington University Human 
Studies Committee. Patients were eligible for treatment with 
intravenous streptokinase if they were evaluated within 8 
hours of the onset of symptoms of myocardial ischemia and 
if they exhibited more than 1 mm of ST segment elevation 
in two contiguous echocardiographic leads and were less 
than 76 years of age. Exclusion criteria included impaired 
hemostasis, recent major surgery, malignancy, long-term 
treatment with anticoagulants or severely limited venous 
access. After written informed consent had been obtained, 
streptokinase was given in doses of 750,000 to 1,000,000 U 
administered intravenously over 1 hour. Administration of 
heparin was initiated when the activated partial thrombo-
plastin time had declined to 2.5 times normal. A bolus 
injection of at least 50 U/kg was followed by a continuous 
infusion of 1,000 U/h subsequently titrated to maintain the 
partial thromboplastin time at 2.5 times control. 
Criteria of coronary recanalization determined prospec-
tively included sudden resolution of ST segment elevation 
with development of Q waves on the electrocardiogram, 
relief of chest pain, sudden ventricular ectopic activity con-
sidered to be indicative of reperfusion arrhythmia and peak-
ing of plasma creatine kinase activity within 10 hours or 
less of the onset of therapy. Serial electrocardiograms were 
obtained before administration of streptokinase, immedi-
ately after the onset of infusion, whenever clinical signs of 
reperfusion occurred and 24 hours after treatment with strep-
tokinase. The presence or absence of reperfusion was de-
termined by two investigators who did not know the fibri-
nopeptide A values. 
Whenever possible, coronary angiography was per-
formed within 48 hours. Patients who were subjected to 
cardiac catheterization later and in whom angiography was 
essential for classification are noted in the text. Coronary 
thrombosis was considered to be present when complete 
occlusion of the infarct-related vessel could be documented 
definitively. 
Acquisition and assay of fibrinopeptide A in blood 
samples. Samples obtained at the time of admission were 
assayed for fibrinopeptide A, creatine kinase MB isoenzyme 
activity (CK-MB), prothrombin time, activated partial 
thromboplastin time, thrombin time, fibrinogen, fibrin-
(ogen) degradation products and euglobulin lysis time. Be-
cause of the risk of spurious elevation of fibrinopeptide A 
in samples drawn inappropriately, samples were obtained 
only by technicians trained specially and evaluated period-
ically by the responsible investigators who evaluated them 
with an explicit quality control protocol (6,8). Fibrinopep-
tide A samples were drawn through a heparin lock flushed 
with heparinized saline solution (100 U/ml) before admin-
istration of streptokinase, before administration of heparin 
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and either 15 or 60 minutes after administration of heparin. 
Samples were obtained for assay of CK-MB activity every 
2 hours for at least 24 hours. 
Prothrombin time, activated partial thromboplastin time, 
thrombin time, antithrombin 3 and euglobulin lysis time 
were assayed conventionally. Fibrinogen was assayed by 
the Ellis method and fibrinogen degradation products with 
the latex bead procedure (9,10). Blood samples for as-
say of fibrinopeptide A were drawn into tubes contain-
ing 1.58 x 10- 1 M ethylenediaminetetraacetic acid and 
1.47 X 106 KIUlliter aprotinin, cooled rapidly to 0 to 4°C, 
centrifuged immediately at 1.000 g, frozen at - 20°C for 
24 hours and maintained at - 70°C before radioimmuno-
assay with antibody provided by Mallinckrodt, Inc. The 
upper limit of normal for fibrinopeptide A in our laboratory 
is 2.0 ng/ml (6). Samples for CK-MB were drawn in tubes 
containing 8 ruM ethyleneglycoltetraacetic acid and 12 ruM 
mercaptoethanol, centrifuged immediately, refrigerated and 
assayed within 10 hours as described previously (II). 
Separation of fibrinopeptide A by gel chromatogra-
phy for exclusion of fibrinogen degradation products. A 
1 x 18 em Sephadex G-50 column was equilibrated with 
120 ruM sodium chloride, 2.7 ruM potassium chloride, and 
10 ruM phosphate buffer pH 7.4, saturated with bovine 
serum albumin and washed with the same buffer until the 
effluent had an optical density of less than 0.01. Fibrino-
peptide A standard (200 J.tI, 40 ng/ml) or a bentonite-treated 
patient plasma sample was applied to the column and eluted 
with equilibrating buffer. Each 0 to 73 fraction containing 
fibtinopeptide A was identified by radioimmunoassay of 
fibrinopeptide A. 
Statistical analysis. Data are reported as mean ± SE. 
Fibrinopeptide A, CK-MB and partial thromboplastin values 
and time from onset of symptoms to treatment were nor-
malized by log transformation before statistical analysis with 
t tests and a repeated measures analysis of variance with 
the use of the SAS statistical program (SAS Institute) and 
the computer facilities of the Washington University Bio-
medical Computer Laboratory. 
Results 
Clinical observations. Deep Q waves indicative of 
transmural myocardial infarction developed in 17 of the 19 
patients. Infarction was excluded in one patient; in the other 
patient, non-Q wave infarction was present. Twelve patients 
with transmural infarction manifested criteria for initial re-
canalization after administration of streptokinase (Table 1). 
Recurrent chest pain, echocardiographic changes and ele-
vations of CK-MB were not observed in 9 of these 12 
patients (Group I). The other three patients with criteria of 
initial recanalization manifested recurrent chest pain, ST 
segment elevation and elevation of CK-MB indicative of 
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Table 1. Criteria of Reperfu~ion 
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Time to Peak CK (hour;,) 
ECG Documentation by 
Patient No. Group After On;,et of Symptom, After On;,et of SK Criteria Present Coronary Angiography 
PatIent;, With Imtlal ReperfuslOn 
I 135 9.0 Yes Ye, 
2 145 65 Ye;, No 
3 19.0 10.0 Ye, Yes 
4 8.0 5.5 Ye, No 
5 16.0 100 Yes No 
6 8.5 75 Yes Yes 
7 11.0 9.0 Yes Yes 
8 8.25 6.0 Yes Yes 
9 8.5 6.0 Yes Yes 
10 II 11.5 70 Yes Yes 
II II 9.75 675 Yes Yes 
12 II 90 725 Yes No 
Total (n = 12) 1I.5±IO 7.54 ± 0.5 12/12 8112 
Patients Without Reperfusion 
13 III 25.5 190 None Yes 
14 III 24.5 21 None No 
15 III 21.0 12.5 None No 
16 III 18 11.5 None Yes 
17 III 19.0 16.0 None Yes 
Total (n = 5) 21.6 ± 1.5* 17 6 ± 25* 0/5 3/5 
Data expressed as mean ± SE. *p < 0.001 between patients with and without reperfuslOn CK = creatine kinase; ECG = electrocardiographic; 
SK = streptokinase 
reinfarction (Group 11). Five other patients did not exhibit 
criteria of initial recanalization (Group III). The character-
istics of each of these three groups are shown in Table 2. 
Age, gender and locus of infarction were similar among 
them. In patients with apparent initial failure of recanali-
zation, administration of streptokinase had been initiated 
somewhat, but not significantly, later after the onset of 
symptoms (5.4 ± 1.1 hours compared with 4.0 ± 0.9 
[Group I] and 3.2 ± 0.7 hours [Group II] [p = 0.14]). No 
bleeding complications requiring transfusion were encoun-
tered. The two patients without transmural infarction were 
considered separately. 
Table 2. Group Comparisons 
Group I. Lysis 
Variable (n = 9) 
Gender 6M/3F 
Age (yr) ( ± SO) 59.7 ± 2.9 
Locus of myocardial infarction 6 ANT/3 INF 
Time from on,et to 4.0 ± 09 
admini,tration of 
streptokmase (hours) 
ImtIal fibnnopeptIde A (ng/ml) 84.9 ± 38 I 
Coronary angiography. This procedure was performed 
in 11 patients. In aU, angiography confirmed the clinical 
impression. Each of the three patients with successful re-
canalization who did not undergo angiography exhibited 
prompt, early peaking of plasma creatine kinase activity 
(6.5, 5.5 and 10 hours after treatment, respectively) and 
electrocardiographic changes indicative of reperfusion. The 
two patients who did not manifest criteria of thrombolysis 
and who did not undergo angiography exhibited plasma CK 
values that peaked 21 and 12.5 hours after treatment, that 
is, 21 and 24.5 hours, respectively, after the onset of symp-
toms. Two of the three patients with reinfarction underwent 
Group II. Reocclw,ion Group III, Nonlysls 
(n = 3) (n = 5) 
IM/2F 4MIlF 
530 ± 4.9 57.6 ± 3 I 
2 ANTII INF 2 ANT/3 INF 
32 ± 07 54 ± I I 
49.2 ± 11.7 87.8 ± 692 
ANT = anterior Infarct; F = female. INF = Inferior Infarct. M = male. 
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Table 3. Changes in Coagulation Vanables 
Variable 
ActIvated partIal thromboplastin time (seconds) (norm = 26 to 37) 
Baseline 
After streptokinase 
After heparin 
Fibrinogen (mg/ml) (norm = 150 to 360) 
BaselIne 
After streptokinase 
FIbrinogen degradatIOn product (j.Lg/ml) (norm < 8.0) 
Baseline 
After streptokmase 
Data expressed as mean ± SE. norm = normal value. 
coronary angiography, one immediately after reinfarction 
and one later after the onset of symptoms suggestive of 
recurrent infarction. The one patient with a non-Q wave 
infarction had a 60% occlusion of the infarct-related vessel. 
Evaluation of the lytic state. In all patients in each of 
the three groups, a systemic lytic state reflecting the elab-
oration of plasmin in the circulating blood was evident (Ta-
ble 3). Criteria of intact hemostasis were comparable in all 
three groups before administration of streptokinase. Before 
administration of heparin, the partial thromboplastin time 
was prolonged in all patients. In four patients with initial 
recanalization (Group I), one without (Group III) and all 
three patients with initial recanalization followed by reoc-
clusion (Group II) the partial thromboplastin time had de-
Figure 1. Group L Serial fibrinopeptide A (FPA) values in patients 
with reperfusion (n = 9). The circled value indicates the value 
in a sample that had been obtained only with difficulty and it may 
be spuriously elevated. 
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Group I. 
Reperfusion 
(n = 9) 
30.4 ± 3 3 
72.4 ± 12.9 
717 ± 172 
3441 ± 606 
152.9 ± 31.8 
170 ± 8.9 
268.9 ± 168.9 
Group II. 
ReoccluslOn 
(n = 3) 
25.5 ± 0.8 
482 ± 1.2 
972 ± 26.7 
341.7 ± 73.7 
1367 ± 23.5 
2.0 ± 1.0 
1,845.3 ± 1.639.5 
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Group III. 
No ReperfuslOn 
(n = 5) 
29.8 ± 2.8 
96 2 ± 22.5 
104.6 ± 18.7 
355.6 ± 29.9 
153.8 ± 21.6 
6.0 ± 2.8 
153.6 ± 91.5 
creased to below two times control after streptokinase but 
before administration of heparin. After the first dose of 
heparin. partial thromboplastin time was greater than 2.5 
times control in every patient. It fell to less than 2 times 
control while heparin was being infused only in four patients 
with initial recanalization. None exhibited criteria of rein-
farction. The apparent difference in values for fibrinogen 
degradation products in Groups I and III and Group II were 
not statistically significant and were attributable primarily 
to the values of one patient in Group II with a marked 
elevation of degradation products (> 5,120 /Lg/ml). 
Values for fibrinopeptide A. Initial fibrinopeptide A 
values were elevated markedly (>8 ng/ml) in patients with 
transmural infarction and were comparable among Group I 
patients with initially successful recanalization (n = 9) com-
pared with Group III patients without recanalization (n = 
5) (84.9 ± 38.1 and 87.8 ± 69.2 ng/ml, respectively). 
Initial fibrinopeptide A averaged 49.2 ± 11.7 ng/ml in 
patients with initial recanalization followed by reocclusion 
(Group II). 
By the time heparin was initiated, 3.5 ± 1 hours after 
initial treatment with streptokinase, marked differences in 
plasma fibrinopeptide A values were evident among the 
three groups. In patients with persistent recanalization (Group 
I), fibrinopeptide A had declined by 88% when partial 
thromboplastin time had declined to 2.5 times control. Fi-
brinopeptide A values in this group changed very little after 
administration of heparin (Fig. 1). In the five patients with-
out initial recanalization (Group III), fibrinopeptide A in-
creased with time despite prolongation of the partial throm-
boplastin time after administration of streptokinase. Before 
administration of heparin, fibrinopeptide A values exceeded 
initial values by 57%, having risen markedly in four of the 
five patients. Within 1 hour after administration of heparin, 
fibrinopeptide A fell markedly to less than 50% of values 
in samples before administration of heparin (Fig. 2). 
Among the three patients with recanalization in whom 
reinfarction occurred (Group II), elevation of fibrinopeptide 
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A was of a magnitude similar to that in patients without 
initially successful recanalization. However, the partial 
thromboplastin time was less prolonged than that in patients 
without initial recanalization. After administration of hep-
arin, partial thromboplastin time exceeded two times control 
in all patients in this group. However. fibrinopeptide A 
remained markedly elevated (83.3 ± 21.4 ng/m!) (Fig. 3). 
Elevations evident 15 minutes after administration of hep-
arin persisted in samples drawn 1 hour later. 
These patterns of response of fibrinopeptide A to strep-
tokinase and to heparin were significantly different in the 
three groups of patients with transmural infarction (p < 
0.05, by analysis of variance for repeated measures) (Fig. 
4). In the two patients in whom transmural infarction was 
excluded despite the induction of a fibrinolytic state com-
parable with that in Groups I. II and III (data not shown), 
minimally elevated levels of fibrinopeptide A initially changed 
only slightly after administration of streptokinase and hep-
arin (Fig. 5). 
In samples with marked elevations of jibrinopeptide A, 
assays were repeated after gel filtration chromatography of 
the samples, on Sephadex 50 by radioimmunoassay of the 
column eluate. Fibrinopeptide A immunoreactivity was ev-
ident only in fractions containing low molecular weight 
species excluding immunoreactivity of the fibrinopeptide A 
antibody with large fibrinogen degradation fragments such 
as X. Y or E. 
Figure 2. Group III. Serial fibrinopeptide A (FPA) values in 
patients without reperfusion (n = 5). In contrast to Figure I. values 
rise concomitantly with administration of streptokinase but decline 
after heparin. The circled value indicates the value in a sample 
obtained only with difficulty and it may be spuriously elevated. 
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Figure 3. Group II. Serial fibrinopeptide A values in patients with 
reperfusion and reocclusion (n = 3). Values rise concomitantly 
with administration of streptokinase and do not decline sharply 
after administration of heparin. in contrast to Figure 2. 
Antithrombin 3 was measured in samples from patients 
in whom fibrinopeptide A did not plummet in response to 
heparin. Values were normal in each case, indicating that 
induction of anticoagulant activity by heparin was not com-
promised and could not account for the persistent elevations 
of fibrinopeptide A. 
Discussion 
The results obtained in this study indicate that coronary 
thrombolysis with streptokinase is associated generally with 
a decline in activation of thrombin in vivo reflected by 
diminution of fibrinopeptide A activity in plasma, and that 
both initial failure of recanalization and reocclusion early 
after initial success may reflect excessive, persistent acti-
vation of thrombin in vivo. 
We have shown previously (6) that fibrinopeptide A in 
plasma is markedly elevated early after the onset of symp-
toms of transmural myocardial infarction and that values 
generally decline over the subsequent 24 hours. In samples 
obtained more than 10 hours after the onset of transmural 
infarction or in those from patients with non-Q wave in-
farction, marked elevations of fibrinopeptide A are absent. 
In view of the prompt reduction in fihrinopeptide A after 
administration of heparin and the lack of a relation between 
the magnitude of elevation of fibrinopeptide A and the extent 
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of infarction assessed by serial assays of CK-MB, fibrino-
peptide A appears to be a marker of coronary thrombosis 
in this setting. 
Lack of cross-reactivity of fibrin(ogen) degradation 
products in the fibrinopeptide A assay system. 
Radioimmunoassay results for fibrinopeptide A in samples 
from patients treated with streptokinase may be confounded 
by immunologic cross-reactivity of the antibody used with 
relatively large fibrinogen degradation fragments containing 
the NH2 terminus of fibrinogen (12). Greater specificity can 
be achieved with some antibodies (2) such as those used in 
Figure 5. Serial fibrinopeptide A (FPA) values in two patients 
without transmural infarction. Fibrinopeptide A did not increase 
despite fibrinogenolysis. SK = streptokinase. 
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our study. The following factors argue strongly against cross-
reactivity of fibrinogen degradation products in the assay 
system used in this study: the observed reduction of fibri-
nopeptide A after administration of streptokinase in patients 
exhibiting recanalization; the lack of elevation of fibrino-
peptide A after administration of streptokinase despite marked 
elevations of fibrinogen degradation products in samples 
from patients without transmural infarction; the prompt de-
crease of fibrinopeptide A after administration of heparin in 
most patients while the concentration of fibrinogen degra-
dation products in plasma continued to increase; and the 
distribution of fibrinopeptide A immunoreactivity in frac-
tions separated by gel filtration columns. 
Cross-reactivity of our fibrinopeptide A assay with the 
alpha 1-23 fibrinogen product of proteolysis induced by 
plasmin cannot be excluded unequivocally (13,14). In our 
study, elevations of fibrinopeptide A did not occur in pa-
tients without transmural infarction, despite administration 
of streptokinase which would have elicited production of 
this product with cross-reactivity if it were detectable. Thus, 
our assay, similar to the assays of Nossel et al. (15) and 
Kockum (14), appears to be free from significant influence 
by the alpha 1-23 product. 
Thrombosis and thrombolysis: a precarious bal-
ance. Our results indicate that a relative balance between 
ongoing activation of thrombin and thrombolysis is a major 
determinant of the success or failure of persistent recanal-
ization after coronary thrombolysis, Activation of plasmin-
ogen in the systemic circulation does not necessarily assure 
a successful clinical outcome (1). Reocclusion after initial 
recanalization occurs in as many as 43% of patients (16), 
especially when high grade residual stenosis is present (17). 
Accordingly, heparin or antiplatelet drugs, or both, are gen-
erally used concomitantly with activators of the fibrinolytic 
system, However, judging from our results, successful re-
canalization appears to be associated with a reduction in 
activation of thrombin before administration of heparin. Thus, 
activation of plasminogen may elicit a reduction in endog-
enous stimuli to thrombosis, The propensity toward acti-
vation of thrombin initially present may be modulated by 
local factors such as activation of protein C by thrombo-
modulin (18) or by accumulating fibrinogen degradation 
products with antithrombin effects, such as X, Y and E 
(19,20). 
Mechanisms contributing to an imbalance between on-
going activation of thrombin (thrombosis) and lytic activity 
(thrombolysis) in patients in whom recanalization is not 
persistent have not yet been elucidated. Patients without 
persistent recanalization manifest more intense and more 
persistent activation of thrombin than that seen in patients 
with successful recanalization. The increased predilection 
to thrombosis may reflect reduced inhibition by thrombo-
modulin activation of protein C (18), persistence of greater 
amounts of functional thrombin within the thrombus or high 
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grade residual stenosis (17,21), among other factors. Rel-
ative or absolute differences in concentrations of higher 
molecular weight fibrinogen degradation products, such 
as X, Y or E, that inhibit activation of thrombin may 
contribute (19,20). 
Patients with initial recanalization followed by reocclu-
sion exhibit serial changes of plasma fibrinopeptide A sim-
ilar to those in patients without initially successful reca-
nalization. The pattern appears to be indicative of ongoing 
activation of thrombin in both. Pharmacologically induced 
lysis may predominate initially, despite marked underlying 
ongoing activation of thrombin in juxtaposition to high grade 
residual stenosis (17). With time, however, the ongoing 
activation of thrombin may predominate, with consequent 
reocclusion. The high propensity to thrombosis implicated 
by persistent elevations of fibrinopeptide A despite hep-
arinization implies that more aggressive or earlier admin-
istration of heparin might prevent reocclusion in appropriate 
patients. Some patients with acute myocardial infarction 
require large amounts of heparin to inhibit production of 
fibrinopeptide A (7). This could be due to deficiency of 
antithrombin 3 (heparin cofactor); however, antithrombin 3 
values were normal in our patients with elevations of fibri-
nopeptide A resistant to heparinization. 
Mechanical interventions designed to improve coronary 
patency may be required to prevent reocclusion. Neverthe-
less, patients prone to early reocclusion may be identifiable 
prospectively because of persistent elevations of fibrino-
peptide A despite adequate heparinization. 
Imbalance between thrombosis and thrombolysis is a de-
terminant of venous thrombosis in patients recovering from 
surgery (22), and temporally dyssynchronous thrombosis 
and lysis have been documented by analysis of the extent of 
y-y cross-linking in fibrin in clots (23). 
Clinical implications. Although coronary angiography 
was not performed immediately because placement of cath-
eters in the central circulation elevates fibrinopeptide A (24), 
the clinical criteria used prospectively separated groups without 
overlap. Statistically significant differences in the temporal 
pattern of elevations of fibrinopeptide A in plasma were 
observed among groups despite the small numbers of pa-
tients studied. Only in Group II (initial recanalization fol-
lowed by early reocclusion) would a misclassification po-
tentially distort results. The marked resistance of fibrino-
peptide A elevations to administration of heparin was seen 
only in this group. 
The marked reduction in activation of thrombin reflected 
by the rapid decline of plasma fibrinopeptide A in patients 
in whom coronary thrombolysis is successful implies that 
less aggressive anticoagulation than that used routinely may 
suffice for appropriately selected patients, with consequent 
reduction in the risk of bleeding. Alternatively, increases 
in plasma fibrinopeptide A in patients in whom recanali-
zation is not achieved and in those with initial recanalization 
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followed by early reocclusion appear to be indicative of a 
continuing stimulus to thrombosis. Aggressive and early 
anticoagulation or early mechanical revascularization, or 
both, may be needed in patients manifesting this phe-
nomenon. 
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